NCT00100932

Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy

Phase II Study of E7389, a Halichondrin B Analog, in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC), Who Progressed During or After Platinum-Based Doublet Chemotherapy Stratified for Prior Taxane Therapy

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 106 (actual)
• Sponsor: Eisai Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a study of E7389 in patients with recurrent and/or metastatic Non-Small-Cell Lung Cancer (NSCLC) who progressed during or after treatment with a platinum agent and another chemotherapy.

Conditions

• Non-Small-Cell Lung Carcinoma

Interventions

Type	Name	Description
DRUG	E7389 28 Day Cycle	E7389 1.4 mg/m\^2 IV bolus on Days 1, 8, and 15 of a 28 day cycle.
DRUG	E7389 21 Day Cycle	E7389 1.4 mg/m\^2 IV bolus on Days 1 and 8 of a 21 day cycle.

Timeline

• Start date: 2004-12-01
• Primary completion: 2008-06-01
• First posted: 2005-01-10
• Last updated: 2012-03-27
• Results posted: 2012-01-31

Locations

13 sites across 1 country: United States